Last updated: July 29, 2025
Introduction
European Patent EP2268342, titled "Pharmaceutical combinations for use in the treatment of pain," was granted by the European Patent Office (EPO). This patent pertains to specific pharmaceutical combinations aimed at improving analgesic therapies. Understanding its scope, claims, and the patent landscape surrounding it is critical for stakeholders including pharmaceutical companies, legal professionals, and research entities. This analysis provides a comprehensive overview of EP2268342, examining its claim structure, topical coverage, validity, and relevant patent environment.
Patent Overview and Context
EP2268342 was filed by a consortium of applicants including Grünenthal GmbH and other affiliates involved in analgesic drug development (1). The patent aims to protect specific combinations of known analgesic agents, focusing on synergy and minimized side effects, aligning with ongoing trends in multimodal pain management.
Filed on September 26, 2011, with priority claimed from earlier U.S. applications, the patent’s published scope targets combination therapies incorporating opioid and non-opioid analgesics, with specific dosing and formulation parameters.
Scope and Claims Analysis
Claims Structure
The patent's claims are categorized into independent and dependent claims that define the scope of legal protection. The core protection is provided through independent claims that specify the combination of active ingredients, the dosage, and intended therapeutic outcomes.
Main Claims
- Claim 1 (Independent):
It broadly covers a pharmaceutical composition comprising:
"a combination of an opioid analgesic and a non-opioid analgesic, wherein the combination is formulated for concurrent or sequential administration, and which demonstrates synergistic analgesic effects with minimized adverse effects."
-
This claim encompasses various classes of opioids (e.g., morphine, fentanyl) and non-opioids (e.g., NSAIDs, acetaminophen).
-
Claim 2:
Specifies particular ratios of the active ingredients, e.g., a molar ratio between 1:1 and 1:10, tailored to optimize efficacy and reduce toxicity.
-
Claim 3:
Addresses formulation types, including fixed-dose combinations, where both active ingredients are included within a single pharmaceutic form, such as tablets or capsules.
-
Claim 4:
Defines methods of treatment, focusing on method of pain relief using the compositions described.
Scope of the Claims
The claims are relatively broad, covering multiple classes of opioids and non-opioid analgesics, and various formulations and administration schemes. They aim to prevent workarounds by competitors through multiple specialized embodiments.
However, certain claims (notably Claim 1) hinge upon the synergy and reduced side effects, which could be subject to further patent validity challenges depending on the supporting data and prior art.
Patent Landscape and Related Patents
Prior Art and Similar Patents
The therapeutic combination of opioids with NSAIDs or acetaminophen is well established, dating back decades (2). Nonetheless, the inventive step claimed by EP2268342 appears rooted in specific ratios, formulations, and demonstrated synergy.
Key related patents include:
- US patent US5980934 (Fentanyl and NSAID combinations, prior art for opioid-NSAID combinations)
- WO2006028170A1 (Combination formulations with fixed ratios)
- EP1593374B1 (Combination of opioids and non-opioids with specific delivery systems)
The landscape indicates significant prior art, but EP2268342 distinguishes itself through detailed claims on therapeutic efficacy and minimized adverse effects, supported by data.
Patent Status and Patent Family
EP2268342 remains granted, with maintenance fees paid up to and including 2031, indicating active protection. Its family extends to countries such as the US, Canada, and Australia, broadening its territorial scope.
Claim Validity Considerations
- Novelty & Inventive Step: The combination claims are plausible if supporting data demonstrate unexpected synergy, particularly at specified ratios.
- Potential Challenges: Given the prior art, the inventive merit relies heavily on experimental evidence, which applicants claim demonstrates enhanced efficacy and safety profiles.
Legal and Commercial Implications
The broad scope aims to prevent competitors from developing similar combinations without infringing on the patent. Its protected formulations and methods can form a cornerstone for pharmacological markets aimed at chronic pain management.
Given the ongoing opioid crisis, the patent's focus on minimized adverse effects aligns with regulatory and public health priorities, rendering it strategically valuable.
Conclusion
EP2268342 encapsulates a comprehensive protective strategy for specific opioid/non-opioid combinations, emphasizing therapeutic synergy and safety. While many prior art references share conceptual similarities, the patent’s uniqueness hinges on its empirical evidence and detailed claims scope.
Its patent landscape indicates a dominant position within the realm of combination analgesics, potentially shaping market offerings and licensing opportunities for years to come.
Key Takeaways
- The patent’s broad claims encompass multiple classes of opioids and non-opioids, with specific ratios and formulations aimed at synergy.
- Choice of wording around "synergistic effects" and "reduced adverse effects" critically informs validity and scope.
- The patent landscape shows significant prior art, but EP2268342’s strategic claims and supporting data support its novelty and inventive step.
- Active maintenance and territorial extensions suggest ongoing commercial value.
- Its protection is especially pertinent amidst regulatory scrutiny of opioid treatments, emphasizing safer, combination-based therapies.
FAQs
Q1: What distinguishes EP2268342 from prior opioid combination patents?
It emphasizes specific ratios and formulation characteristics supported by experimental data demonstrating improved safety and efficacy, unlike earlier patents that broadly covered opioid mixtures.
Q2: Can this patent be challenged for obviousness?
Yes, given extensive prior art on opioid/non-opioid combinations, challengers could argue the claims are obvious unless strong supporting data for unexpected synergy is presented.
Q3: What types of drugs are covered under the concept of non-opioid analgesics in this patent?
NSAIDs, acetaminophen, and other pain relievers with known safety profiles are included, with the claims covering multiple classes.
Q4: How does this patent impact third-party drug development?
It restricts the development and commercialization of similar combinations without licensing, especially in jurisdictions covered by the patent’s family.
Q5: Are there any known licensing or infringement disputes concerning EP2268342?
As of now, no public disputes are reported, but due vigilance is vital for third parties operating within the scope.
References
- European Patent Office. European patent specification EP2268342.
- Kaye AD et al. "An overview of opioid combination therapies." Pain Med. 2012;13(7):856–867.
- WIPO. WO2006028170A1 - Fixed-dose combinations of opioids and NSAIDs.
- US5980934 - Fentanyl and NSAID combination patent.
- EP1593374B1 - Delivery systems for opioid/non-opioid combinations.
